Dr. Kunlin Cao, President of Keya Medical R&D, participated in the Cardiovascular Disease Imaging Forum at QICCD 2020 alongside Dr. Pengfei Zhang of Shangdong University.
Dr. Kunlin Cao delivered a keynote address at the China AI in Medical Imaging Conference on Keya Medical’s experience bringing AI-powered medical imaging solutions to clinical use.
Recent research demonstrates applications for CCTA to be used as the default test for evaluating patients with stable chest pain.
On Sept. 18, Keya Medical was recognized as the winner of of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
The DEEPVESSEL FFR Analysis platform securely processes coronary CTA data provided by health systems.